Hudson Edge Investment Partners Inc. Has $7.37 Million Position in AbbVie Inc. $ABBV

Hudson Edge Investment Partners Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 7.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,807 shares of the company’s stock after selling 2,700 shares during the period. AbbVie accounts for about 1.2% of Hudson Edge Investment Partners Inc.’s holdings, making the stock its 27th biggest holding. Hudson Edge Investment Partners Inc.’s holdings in AbbVie were worth $7,365,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the second quarter worth $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $39,000. Finally, Bear Mountain Capital Inc. increased its holdings in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on ABBV. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Morgan Stanley increased their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. UBS Group reiterated a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Finally, Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Price Performance

ABBV opened at $216.13 on Thursday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm has a market capitalization of $381.98 billion, a P/E ratio of 163.73, a price-to-earnings-growth ratio of 0.87 and a beta of 0.36. The company has a fifty day moving average price of $226.15 and a 200-day moving average price of $216.99.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the company earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.